Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Genetics' Q3 Revenues Climb 41 Percent

NEW YORK (GenomeWeb News) – Interleukin Genetics announced after the close of the market Thursday that revenues for the third quarter rose 41 percent year over year.

Total revenues increased to $765,416 for the three months ended Sept. 30, from $544,744 a year ago, as genetic testing service revenue rose 38 percent to $731,194 from $531,151. Other revenues came in at $34,222, up 152 percent from $13,593 a year ago.

The firm's net loss for the quarter narrowed to $1.1 million, or $.03 per share, from $1.4 million, or $.04 per share, for the third quarter a year ago.

Its spending on R&D inched up 2 percent to $324,669 from $317,155 year over year, while SG&A costs decreased 8 percent to $1.1 million from $1.2 million.

The Waltham, Mass.-based genetic test development firm closed out the third quarter with $1 million in cash and cash equivalents.

In a statement, Interleukin CEO Lewis Bender noted continued revenue growth in the firm's weight management genetic test and wellness select combination products. Enrollment in the company's clinical study for its PST genetic test for periodontal disease with Renaissance Health and the University of Michigan is also progressing, with about 3,300 patients enrolled, he said. The company is targeting 4,000 patients for the study.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.